Stephen Sullivan, PhD, MBA
Managing Director, Lindville Bio
Dr Sullivan is the Managing Director of Lindville Bio, an ATMP consultancy service specializing in the scalable manufacture of Pluripotent Stem Cells (PSC/iPSC) and therapeutic development therefrom.
Dr Sullivan initially earned his PhD at the Roslin Institute (Edinburgh), under Professor Ian Wilmut and Dr Jim McWhir, becoming one of the first researchers in Europe to culture human embryonic stem cells. His work focused on pluripotency induction in human somatic cells.
Thereafter, Dr Sullivan worked as a Research Fellow at the University of Cambridge, Harvard University, and UCSD deepening his expertise of other human stem cell types (including induced pluripotent stem cells) and their medical applications.
Thereafter, he also worked for Novartis, dealing with clinical trial management and compliance, to better understand manufacturing, logistic, and regulatory challenges to bringing new therapeutics to market and earned an MBA at Trinity College Dublin focusing on risk mitigation during AMTP development. With more than 20 years’ experience in the ATMP space, he focuses on the development and translation of pluripotent and induced-pluripotent stem cell therapeutics to the clinic.